New Depot Formulation of LHRH Analogue Allows 12-Week Dosing

Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

LAS VEGAS--A new, longer duration formulation of an LHRH (luteinizing hormone releasing hormone) analogue for advanced prostate cancer offers more convenient dosing and appears to be safe and effective.

LAS VEGAS--A new, longer duration formulation of an LHRH (luteinizinghormone releasing hormone) analogue for advanced prostate canceroffers more convenient dosing and appears to be safe and effective.

Two randomized studies presented at the American Urological Associationannual meeting compared the new formulation, a 10.8 mg depot ofgoserelin acetate (Zoladex), with the 3.6 mg depot of the sameagent.

At a poster session, Frans N.J. Debruyne, MD, University Hospital,Nijmegen, the Netherlands, said that while the 3.6 mg depot requiresmonthly visits to physician offices or clinics, the 10.8 mg depotis replaced at 3 months, an interval coinciding perfectly withthe follow-up schedule of patients with metastatic prostate cancer.

In the two comparative studies presented by Dr. Debruyne, involvinga total of 160 patients with advanced prostate cancer, patientsreceived either a single 10.8 mg depot or three consecutive 3.6mg depots over weeks 0 to 12. Subsequently, all patients receivedthree consecutive 10.8 mg depots over weeks 12 to 48.

Evaluations of the testosterone profiles of patients receivingthe different regimens revealed similar patterns. The expectedtestosterone level rise in the first week was followed by rapiddeclines to within the castrate range by day 21. Mean testosteronelevels in both studies during weeks 4 to 12 were 0.64 nmol/L and0.69 nmol/L for the 10.8 mg and 3.6 mg depot groups, respectively(P = .53).

Levels remained in the castrate range (0 to 2.50 nmol/L) throughoutthe 48-week study period, Dr. Debruyne told Oncology News International.

Adverse events (mostly hot flushes) for patients receiving the10.8 mg depot were comparable to those seen in the 3.6 mg depotgroup. Also, the depot was well tolerated locally, with injectionsite reactions reported for only 0.3% (2) of 614 administrations.

"These studies demonstrate that the new 10.8 mg depot ispharmacody-namically equivalent to the current 3.6 mg depot witha similar safety profile," Dr. Debruyne said. "It willoffer improved convenience to both patients and clinicians."He added that the 12-week dosing would be likely to improve complianceand reduce the costs associated with depot administration.

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Related Content